Trans-Pacific Multicenter Collaborative Study of Minimally Invasive

Status Recruiting

Clinical Trial Summary

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Clinical Trial Description

Primary Objectives: - Delineate the short-term appetite of patients who undergo minimally-invasive proximal gastrectomy (MIPG) and compare them with those of patients with gastric and gastroesophageal adenocarcinoma who undergo total gastrectomy (MITG). We hypothesize that MIPG is associated with better postoperative appetite levels compared to MITG, which would result in improved nutritional status and maintained body weight after surgery. Secondary Objectives: - Assess patient-reported outcomes (PROs) and nutrition measures. We will use the MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI) questionnaire with additional three experimental question items ("PRO questionnaire") to collect preoperative and postoperative patient-reported outcomes (PROs) of QoL and check fasting ghrelin levels to correlate them with reported appetite levels. We will also retrospectively investigate factors associated with improved QoL after surgery, safety of MIPG and MITG, and oncological outcomes after MIPG and MITG. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05205343
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact	Naruhiko Ikoma, MD
Phone	(832) 729-2675
Email	nikoma@mdanderson.org
Status	Recruiting
Phase
Start date	May 11, 2022
Completion date	May 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04544046` - Supportive Oncology Care At Home RCT	N/A
Not yet recruiting	`NCT04555304` - Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy	Phase 2
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT04099641` - An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients	Phase 2
Not yet recruiting	`NCT05431738` - Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)	N/A
Recruiting	`NCT04385641` - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer	N/A
Completed	`NCT03165994` - APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers	Phase 2
Active, not recruiting	`NCT03279237` - A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers	Phase 1
Completed	`NCT03321630` - A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies	Phase 2
Completed	`NCT02853474` - Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy	Phase 3
Active, not recruiting	`NCT03983954` - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT06138223` - The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)	N/A
Active, not recruiting	`NCT03647969` - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT05122091` - Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma	Phase 2
Completed	`NCT03720678` - A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies	Phase 1
Not yet recruiting	`NCT06356311` - A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)	Phase 3
Completed	`NCT02317991` - Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer	Phase 2
Completed	`NCT02013154` - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab	Phase 1
Terminated	`NCT05395052` - FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03490292` - Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer	Phase 1/Phase 2

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms